Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Genetic mutations: New therapeutic avenues in metastatic prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.02.18
Views: 577
Rating:

Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Dr Mateo speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about findings from a retrospective and international study showing for the first time that patients with inherited DNA repair mutations benefit from standard therapies in a similar way to other metastatic prostate cancer patients.

He states that results were analysed for a total of 390 metastatic prostate cancer patients with DNA-repair gene mutations to assess response to standard treatments.

He goes on to highlight that findings indicate that patients with BRCA mutations respond to these therapies in a similar way to other patients with metastatic prostate cancer patients without these mutations. Overall survival and disease-free progression were therefore comparable and no significant differences in response rate to first-line treatment were observed. 

Related videos

follow us

NCRI 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation